InvestorsHub Logo
Followers 58
Posts 10322
Boards Moderated 1
Alias Born 09/21/2016

Re: nidan7500 post# 195259

Monday, 06/03/2019 9:24:48 AM

Monday, June 03, 2019 9:24:48 AM

Post# of 470103

The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer's disease patients. Key performance measures will be collected over 6 months, at up to seven (7) sites in Australia.
COGNISION™ is an easy to use, reliable system that provides physiological measures of cognitive processing ("cognitive biomarkers"). These biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of targeted drug effects.



https://www.prnewswire.com/news-releases/neuronetrix-has-been-selected-by-anavex-life-sciences-corp-to-support-the-upcoming-phase-2a-clinical-trial-for-anavex-2-73-281898201.html

This kind of science is the opposite of the old school DART BOARD.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News